Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

iOnctura taps European syndicate for series A to bring two ‘best-in-class’ programs to the clinic

Created to house programs spun out from Merck KGaA and CRUK, iOnctura prepares for first-in-human studies

Paul Bonanos, Associate Editor
January 24, 2020 8:17 PM UTC

On the strength of its new €15 million ($16.6 million) series A round, iOnctura believes it can have two best-in-class oncology candidates in the clinic within a year.

Created in 2017 by former Merck KGaA (Xetra:MRK) executive Catherine Pickering in partnership with Cancer Research UK to house molecules spun out from both organizations, iOnctura B.V. has attracted an investor syndicate to fund development of two programs it considers its top priorities: a selective PI3Kδ inhibitor and an autotaxin inhibitor...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

iOnctura S.A.